Savara SVRA Return on equity

Return on equity at other companies

XER

Xeris Biopharma Holdings, Inc.XERS

-209.8%—

Innoviva, Inc.INVA

29.1%—

Zevra Therapeutics, Inc.ZVRA

34.8%+31.3pp

Upstream Bio, Inc.UPB

-41.8%—

ANI PharmaceuticalsANIP

21%+19.1pp

PVL

Palvella TherapeuticsPVLA

-34.2%—

FAQ

What is Savara's return on equity?

Savara (SVRA) reported return on equity of -80% in Q1 2026.

How has Savara's return on equity changed year-over-year?

Savara's return on equity decreased by 5.5% year-over-year, from -75.8% to -80%.

What is the long-term trend for Savara's return on equity?

Over 5 years (2020 to 2025), Savara's return on equity has grown at a 1.2% compound annual growth rate (CAGR), from -59.7% to -63.5%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.